Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Base building ⢠Repeated resistance ⢠Weak momentum Support Level: $25.70-$25.90 Resistance Level: $26.90-$27.60 NVST has been choppy over the last month, with base-building above $25.74 and higher lows, but repeated failures near $26.9-$27.6 and weak momentum keep the setup mildly negative unless resistance breaks.
Sentiment & News
Key News Insights: ⢠Growth initiatives ⢠External pressures ⢠Q2 catalyst Envista is pushing growth through new products, acquisitions, and global expansion, but ongoing macro, tariff, and currency pressures continue to weigh on the stock ahead of its Aug. 5 Q2 update.
AI Summary
NVST looks like a credible but still unproven turnaround-with-momentum story: management is executing on products, acquisitions, and expansion, yet tariffs, FX, and a high valuation are capping upside until the company can show durable cash flow and margin expansion, ideally confirmed by a clear break above the $27 resistance zone.
Description
Envista Holdings Corp., headquartered in Brea, California, manufactures and sells a broad range of dental products and tools and employs about 12,800 full-time staff. The company operates two reporting segments: Specialty Products & Technologies, which supplies dental implant and prosthetic systems, orthodontic products and related treatment software; and Equipment & Consumables, which provides dental office equipment, imaging and visualization systems, restorative and endodontic materials, and infection-prevention supplies. Its offerings support diagnosis, treatment and routine clinical procedures across general and specialty dental practices.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 10 | Feb 17 | NVST | Envista Holdings Corp | Envista presents strong Q4 2025 beats, positive analyst upgrades, a raised full-year guidance, robust institutional buying, and a ~24% price gain with breakout above 21-day SMA, supported by product momentum in implants and imaging, though tariff and macro risks temper short-term certainty. | Closed | -7.0% |